<i>Roseburia intestinalis</i>: A Beneficial Gut Organism From the Discoveries in Genus and Species.

Nie K, Ma K, Luo W, Shen Z, Yang Z, Xiao M, Tong T, Yang Y, Wang X. · 2021

Read <i>Roseburia intestinalis</i>: A Beneficial Gut Organism From the Discoveries in Genus and Species. by Nie K, Ma K, Luo W, Shen Z, Yang Z, Xiao M, Tong T, Yang Y, Wang X. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8647967.txt.

Introduction

Nie and co-authors review a gut bacterium, Roseburia intestinalis, and its links to human health. This anaerobic bacterium lives in the colon and makes butyrate, a useful fuel for gut cells. It has been tied to gut inflammation control and energy balance. Levels of the bacterium shift in several diseases.

The review covers bowel disease, type 2 diabetes, and artery disease. In bowel disease, patients show clear changes in the bacterium's abundance. Its products help guard the gut wall and tune immune cells. New tools, such as single-cell sequencing, have deepened work on this group. The authors weigh its promise as a future therapy.

Catalog record

CREATORNie K, Ma K, Luo W, Shen Z, Yang Z, Xiao M, Tong T, Yang Y, Wang X.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE78 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8647967

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species By Kai Nie, Kejia Ma, Weiwei Luo, Zhaohua Shen, Zhenyu Yang, Mengwei Xiao, Ting Tong, Yuanyuan Yang, Xiaoyan Wang Published in: Frontiers in Cellular and Infection Microbiology DOI: 10.3389/fcimb.2021.757718 ABSTRACT Abstract Roseburia intestinalis is an anaerobic, Gram-positive, slightly curved rod-shaped flagellated bacterium that produces butyrate in the colon. R. intestinalis has been shown to prevent intestinal inflammation and maintain energy homeostasis by producing metabolites. Evidence shows that this bacterium contributes to various diseases, such as inflammatory bowel disease, type 2 diabetes mellitus, antiphospholipid syndrome, and atherosclerosis. This review reveals the potential therapeutic role of R. intestinalis in human diseases. Patients with inflammatory bowel disease exhibit significant changes in R. intestinalis abundance, and they may benefit a lot from modulations targeting R. intestinalis. The data reviewed here demonstrate that R. intestinalis plays its role in regulating barrier homeostasis, immune cells, and cytokine release through its metabolite butyrate, flagellin and other. Recent advancements in the application of primary culture technology, culture omics, single-cell sequencing, and metabonomics technology have improved research on Roseburia and revealed the benefits of this bacterium in human health and disease treatment. Keywords: Roseburia, Roseburia intestinalis, probiotic, inflammatory bowel disease (IBD), microbiome INTRODUCTION Roseburia spp. have been brought to the fore because of their novel role in modulating the gut microbial ecology, immune responses, and the development of human disorders (Tamanai-Shacoori et al., 2017). Roseburia was named in honor of Theodor Rosebury, an American microbiologist, for his groundbreaking contributions to the field of oral microbiome. Roseburia sp. belongs to the phylum Firmicutes, class Clostridia, order Clostridiales, and family Lachnospiraceae (Stackebrandt, 2014). The Roseburia genus has five well-characterized species (Roseburia intestinalis, Roseburia hominis, Roseburia inulinivorans, Roseburia faecis, and Roseburia cecicola), all of which produce short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate (Tamanai-Shacoori et al., 2017). In 2002, Duncan et al. isolated a strain of anaerobic, Gram-positive, slightly curved rod-shaped, and flagellated bacteria from human fecal samples. Subsequent phylogenetic analysis revealed its intimate similarity with R. cecicola and the members of cluster XIVa of Clostridium subphylum; thus, it was named Roseburia intestinalis (Duncan et al., 2002). Among the top 20 most abundant bacteria in the gut microbiome, the R. intestinalis cluster usually accounts for 0.9%–5.0% (mean = 2.3%) of the total microbiota (Hold et al., 2003; Hiippala et al., 2018). R. intestinalis are obligate anaerobes that are difficult to culture. They were firstly isolated from human feces in an M2 medium-based culture system (Louis et al., 2004). It was reported that R. intestinalis XB6B4 can be cultivated under anaerobic conditions at 37°C in a complex medium containing clarified rumen fluid (described in Chassard et al., 2007) and 0%–5% complex substrates (oat spelt xylan, wheat or corn bran, pea fiber, cabbage, and leek) or 0%–3% sugar (xylose or glucose) (Chassard et al., 2007; Mirande et al., 2010). R. intestinalis DSM 14610 was reported to degrade and utilize oligofructose as the sole energy source, but only when acetate was added to a special medium for colon bacteria (Falony et al., 2006). This bacterium can also grow anaerobically at 37°C in lytic/10 anaerobic/F medium or LYBHI medium supplemented with yeast extract, cellobiose, maltose, and cysteine (Zhu, C. et al., 2018; Cornuault et al., 2020). Butyryl-CoA:acetate CoA transferase is the key enzyme that produces butyrate in butyrate-producing bacteria. This enzyme has been detected in R. intestinalis, which endows it with the ability to utilize acetate in order to produce butyrate (Pryde et al., 2002). Previous studies have found that R. intestinalis and Faecalibacterium prausnitzii are the most abundant butyrate-producing bacteria in human feces (Hold et al., 2003; Duncan et al., 2004). R. intestinalis can ferment fibers to produce butyrate in an M2 medium supplemented with wheat starch (Louis et al., 2004). Of note is that butyrate has been reported to exert pervasive anti-inflammatory and metabolic modulation effects in different disease models (Canfora et al., 2015; McNabney and Henagan, 2017). Therefore, R. intestinalis can be applied as a potential probiotic given its ability to produce butyrate. Enteric bacteria use fibers as a source of carbon to produce butyrate. Martinez et al. reported that a whole-grain diet increases the intestinal abundance of R. intestinalis and improves the concentration of interleukin-6 (IL-6, which is linked to metabolic dysfunctions) (Martinez et al., 2013). R. intestinalis also has the ability to ferment xylan and β-mannan, which are common fiber ingredients in the diet (Mirande et al., 2010; Leth et al., 2018; La Rosa et al., 2019). β-mannans and xylans are important components of the plant cell wall, and they are acetylated to protect them from degradation by glycoside hydrolases. β-mannans are widely present in human and animal diets. RiCE2 and RiCE17, two carbohydrate esterases from R. intestinalis, remove acetylations from all positions in complex β-mannans in a complementary manner (Michalak et al., 2020). The growth of R. intestinalis is influenced by the carbon source, symbiont, and anoxia, and also by the pH. It has been discovered that iron can modulate the ability of R. intestinalis to produce butyrate through the pyruvate mechanism: ferredoxin oxidoreductase (PFO) can convert pyruvate to acetyl-CoA (Dostal et al., 2015). In addition, PFO is sensitive to reducing ferredoxin (Dostal et al., 2015). These data show that R. intestinalis uses different carbohydrates as the source of energy and that its growth is susceptible to iron. The human regenerating family member 3 alpha (hREG3α) promotes the growth of R. intestinalis by inhibiting reactive oxygen species (ROS) signaling and induces resistance in mice with dextran sulfate sodium (DSS)-induced colitis (Darnaud et al., 2018). Colonic bacteria compete for the colonic ecological niche through nutrition plunder and preempt niche advantage (Leth et al., 2020). Several external factors, such as diet or antibiotic use, and endogenous factors may affect the ecological niche of R. intestinalis. It has been reported that ultravirulent phage mutants can drive the disruption of R. intestinalis and the ecological niche occupied by other resistant bacteria (Cornuault et al., 2020). This phenomenon reveals that the interactions among bacteria in the gut environment are complex. The structural characteristic of the flagella in R. intestinalis regulates its motion. The flagella help R. intestinalis to penetrate the colonic mucus layer in order to interact with the epithelium. Therefore, R. intestinalis is one of the most abundant butyrate-producing bacteria that adhere to intestinal mucin, facilitating its significant advantages for the probiotic role (Van den Abbeele et al., 2013). According to the guidelines from the World Health Organization (WHO) on the Evaluation of Probiotics in Food issued in 2002, probiotics are viable microorganisms in dietary supplements that, when consumed at certain levels, stabilize the gastrointestinal tract microflora and confer health benefits to the consumer. In addition to our attempts to expand knowledge about R. intestinalis ( Table 1 and Figure 1 ), multiple trials and experiments based on animal models have elaborated the complicated and tight relationship between R. intestinalis and the occurrence of human diseases ( Figure 2 ). Accumulating evidence also supports the probiotic effect of R. intestinalis in the human body, which demonstrates its fundamental benefits in maintaining a healthy homeostasis. However, the vast majority of the studies described the role of R. intestinalis through

Read the complete text